Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Rezafungin (200-400 mg) demonstrated high rates of clinical and mycological responses, with a Surface Under the Cumulative Ranking Curve (SUCRA) score indicating an overall response greater than 60%. In comparison, caspofungin (50-150 mg) and micafungin (100-150 mg) also exhibited high response rates with SUCRA scores over 60%, while fluconazole (400 mg) had the lowest overall response rate at 17%.
• The effectiveness of rezafungin is comparable to that of caspofungin and micafungin, significantly outperforming fluconazole, which had the lowest response rate among the antifungals evaluated.
• No specific population types or subgroups were highlighted in the abstract regarding the effectiveness outcomes.
• Rezafungin (200-400 mg) and micafungin (100 mg) were associated with lower discontinuation rates, both reported to be less than 40%. In contrast, conventional amphotericin B (0.6-0.7 mg/kg) had a high likelihood of discontinuation, with an odds ratio was 0.08, with a 95% credible interval (CrI) of 0.00 to 0.95 compared to caspofungin (150 mg).
• Conventional amphotericin B may impair liver function in 87% of cases, indicating significant safety concerns.
• There is no population types or subgroups information available in the reviewed documents.